Atazanavir/cobicistat
| Combination of | |
|---|---|
| Atazanavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Evotaz |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[2][3] It contains atazanavir and cobicistat.[2][3][4] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.[2]
Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015.[5][6] It was approved for medical use in the European Union in July 2015.[3]
Medical uses
Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).[2][3]
References
- ^ "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
- ^ a b c d e "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
- ^ a b c d e "Evotaz EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 May 2021.
- ^ Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi:10.2147/HIV.S99063. PMC 4790521. PMID 27022304.
- ^ "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.
- ^ "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. "Summary Report" (PDF).
External links
- "Atazanavir mixture with cobicistat". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description is different from Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Antiretroviral drugs
- Drugs developed by Bristol Myers Squibb
- CYP3A4 inhibitors
- Fixed dose combination (antiretroviral)
- All stub articles
- Antiinfective agent stubs